FDA Brief

Warning letters Drugs

FDA warning letter to

Zydus Lifesciences Limited

High riskIssued Aug 29, 2024Posted Sep 10, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.

What happened

FDA inspected Zydus's Jarod, Gujarat drug manufacturing plant from April 15 to 23, 2024. Investigators found the company had not properly investigated repeated cross-contamination between products made on shared equipment, or glass particles found in Cyanocobalamin Injection batches. The company later recalled Verapamil Hydrochloride Injection (July 2, 2024) and Cyanocobalamin Injection (June 27, 2024).

What FDA found

  1. The company did not properly investigate cross-contamination from one drug product into at least several other batches made on the same equipment, and did not consider all affected batches or check whether its cleaning and testing were adequate.

    21 CFR 211.192
  2. It released some batches as clean based on 'not detected' test results without explaining why those samples represented the whole batch.

    21 CFR 211.192
  3. It did not find the root cause of glass particles in multiple Cyanocobalamin Injection batches, but re-inspected batches until results passed and then released them.

    21 CFR 211.192
  4. Operators used poor aseptic technique, reaching over sterile vials and stoppers and touching stoppers during setup on the filling line.

    21 CFR 211.113(b)
  5. Airflow (smoke) studies did not adequately show unidirectional airflow in the critical sterile filling area, and the stopper conveyor track appeared to block first air.

    21 CFR 211.113(b)
  6. Process performance qualification studies lacked statistical sampling plans and acceptance criteria to measure variation within and between batches.

    21 CFR 211.100(a) and 211.100(b)

What FDA wants

FDA tells the company to respond in writing within 15 working days describing what it has done to fix the violations and prevent them recurring, and to provide independent assessments and remediation plans for its investigation, aseptic processing and process validation systems. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • brands and distributors that buy injectable drugs from this site
  • hospitals and clinicians administering Zydus injectables
  • manufacturers running shared equipment lines for multiple products

This is a summary. Read the original letter on fda.gov.

Zydus Lifesciences Limited's FDA history

  1. Zydus Lifesciences Limited

    FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

    High risk

Full company page

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk